Preparation and evaluation of a radiogallium complex-conjugated bisphosphonate as a bone scintigraphy agent

Nuclear Medicine and Biology

Volumn 38, Issue 5, 2011, Pages 631-636

  Ogawa, Kazuma ^a   Takai, Kenichiro ^a   Kanbara, Hiroya ^a   Kiwada, Tatsuto ^a   Kitamura, Yoji ^a   Shiba, Kazuhiro ^a   Odani, Akira ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Bisphosphonate; Bone; DOTA; Gallium; PET

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; GALLIUM 4 [3 (HYDROXY 4,4 BISPHOSPHONOBUTYL)THIOUREIDO]BENZYL 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID GA 67; GALLIUM 68; HYDROXYAPATITE; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BONE SCINTISCANNING; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RADIOCHEMISTRY; RADIOISOTOPE DISTRIBUTION;

ANIMALS; BONE AND BONES; BONE NEOPLASMS; CHELATING AGENTS; DIPHOSPHONATES; DRUG STABILITY; DURAPATITE; GALLIUM RADIOISOTOPES; HALF-LIFE; HETEROCYCLIC COMPOUNDS, 1-RING; MALE; MICE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY;

EID: 79959640611     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.12.004     Document Type: Article

References (30)

1. Subramanian G., McAfee J.G., Blair R.J., Kallfelz F.A., Thomas F.D. Technetium-99m-methylene diphosphonate - a superior agent for skeletal imaging: comparison with other technetium complexes. J Nucl Med 1975, 16:744-755.
2. Domstad P.A., Coupal J.J., Kim E.E., Blake J.S., DeLand F.H. Tc-hydroxymethane diphosphonate: a new bone imaging agent with a low tin content. Radiology 1980, 136:209-211.
3. Love C., Din A.S., Tomas M.B., Kalapparambath T.P., Palestro C.J. Radionuclide bone imaging: an illustrative review. Radiographics 2003, 23:341-358.
4. Mari C., Catafau A., Carrio I. Bone scintigraphy and metabolic disorders. Q J Nucl Med 1999, 43:259-267.
5. Meyer J.L., Nancollas G.H. The influence of multidentate organic phosphonates on the crystal growth of hydroxyapatite. Calcif Tissue Res 1973, 13:295-303.
6. Libson K., Deutsch E., Barnett B.L. Structural characterization of a technetium-99-diphosphonate complex. Implications for the chemistry of technetium-99m skeletal imaging agents. J Am Chem Soc 1980, 102:2476-2478.
7. Ogawa K., Mukai T., Inoue Y., Ono M., Saji H. Development of a novel 99mTc-chelate-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent. J Nucl Med 2006, 47:2042-2047.
8. Verbeke K., Rozenski J., Cleynhens B., Vanbilloen H., de Groot T., Weyns N., et al. Development of a conjugate of 99mTc-EC with aminomethylenediphosphonate in the search for a bone tracer with fast clearance from soft tissue. Bioconjug Chem 2002, 13:16-22.
9. Palma E., Oliveira B.L., Correia J.D., Gano L., Maria L., Santos I.C., et al. A new bisphosphonate-containing 99mTc(I) tricarbonyl complex potentially useful as bone-seeking agent: synthesis and biological evaluation. J Biol Inorg Chem 2007, 12:667-679.
10. de Rosales R.T.M., Finucane C., Mather S.J., Blower P.J. Bifunctional bisphosphonate complexes for the diagnosis and therapy of bone metastases. Chem Commun 2009, 4847-4849.
11. Ogawa K., Mukai T., Arano Y., Hanaoka H., Hashimoto K., Nishimura H., et al. Design of a radiopharmaceutical for the palliation of painful bone metastases: rhenium-186-labeled bisphosphonate derivative. J Labelled Cmp Radiopharm 2004, 47:753-761.
12. Ogawa K., Mukai T., Arano Y., Otaka A., Ueda M., Uehara T., et al. Rhenium-186-monoaminemonoamidedithiol-conjugated bisphosphonate derivatives for bone pain palliation. Nucl Med Biol 2006, 33:513-520.
13. Ogawa K., Mukai T., Arano Y., Ono M., Hanaoka H., Ishino S., et al. Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals. Bioconjug Chem 2005, 16:751-757.
14. Ogawa K., Mukai T., Asano D., Kawashima H., Kinuya S., Shiba K., et al. Therapeutic effects of a 186Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model. J Nucl Med 2007, 48:122-127.
15. Ogawa K., Mukai T., Kawai K., Takamura N., Hanaoka H., Hashimoto K., et al. Usefulness of competitive inhibitors of protein binding for improving the pharmacokinetics of 186Re-MAG3-conjugated bisphosphonate (186Re-MAG3-HBP), an agent for treatment of painful bone metastases. Eur J Nucl Med Mol Imaging 2009, 36:115-121.
16. Uehara T., Jin Z.L., Ogawa K., Akizawa H., Hashimoto K., Nakayama M., et al. Assessment of 186Re chelate-conjugated bisphosphonate for the development of new radiopharmaceuticals for bones. Nucl Med Biol 2007, 34:79-87.
17. Torres Martin de Rosales R., Finucane C., Foster J., Mather S.J., Blower P.J. Re(CO)3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases. Bioconjug Chem 2010, 21:811-815.
18. Ogawa K., Mukai T. Targeted imaging and therapy for bone metastases: control of pharmacokinetics of bone-targeted radiopharmaceuticals. J Drug Deliv Sci Technol 2009, 19:171-176.
19. Vitha T., Kubicek V., Hermann P., Elst L.V., Muller R.N., Kolar Z.I., et al. Lanthanide(III) complexes of bis(phosphonate) monoamide analogues of DOTA: bone-seeking agents for imaging and therapy. J Med Chem 2008, 51:677-683.
20. Ogawa K., Kawashima H., Shiba K., Washiyama K., Yoshimoto M., Kiyono Y., et al. Development of [90Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases. Nucl Med Biol 2009, 36:129-135.
21. Kubicek V., Rudovsky J., Kotek J., Hermann P., Vander Elst L., Muller R.N., et al. A bisphosphonate monoamide analogue of DOTA: a potential agent for bone targeting. J Am Chem Soc 2005, 127:16477-16485.
22. Zhernosekov K.P., Filosofov D.V., Baum R.P., Aschoff P., Bihl H., Razbash A.A., et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007, 48:1741-1748.
23. Fujisawa R., Kuboki Y. Preferential adsorption of dentin and bone acidic proteins on the (100) face of hydroxyapatite crystals. Biochim Biophys Acta 1991, 1075:56-60.
24. Heppeler A., Froidevaux S., Macke H.R., Jermann E., Behe M., Powell P., et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 1999, 5:1974-1981.
25. Goulet R.T., Shysh A., Noujaim A.A. Investigation of 68Ga-tripolyphosphate as a potential bone-scanning agent. Int J Appl Radiat Isot 1975, 26:195-199.
26. Dewanjee M.K., Hnatowich D.J., Beh R. New 68Ga-labeled skeletal-imaging agents for positron scintigraphy. J Nucl Med 1976, 17:1003-1007.
27. Kino I., Kato Y., Lin J.H., Sugiyama Y. Renal handling of biphosphonate alendronate in rats. Biopharm Drug Dispos 1999, 20:193-198.
28. Mitterhauser M., Toegel S., Wadsak W., Lanzenberger R.R., Mien L.K., Kuntner C., et al. Pre vivo, ex vivo and in vivo evaluations of [68Ga]-EDTMP. Nucl Med Biol 2007, 34:391-397.
29. Fellner M., Baum R.P., Kubicek V., Hermann P., Lukes I., Prasad V., et al. PET/CT imaging of osteoblastic bone metastases with 68Ga-bisphosphonates: first human study. Eur J Nucl Med Mol Imaging 2010.
30. van Beek E., Hoekstra M., van de Ruit M., Lowik C., Papapoulos S. Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 1994, 9:1875-1882.